Indication
Agamree is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.
Loading your page…
Loading your page…
Muscular Dystrophy, Duchenne
Marketing Authorisation Holder: Santhera Pharmaceuticals (Deutschland) GmbH
EMA Authorisation: 14/12/2023
INN: vamorolone
AI Drug & Interaction Analysis
Free account required
Ask Osler about Agamree: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.